PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
CHICAGO, June 02, 2025--(BUSINESS WIRE)--PanGIA Biotech, a leader in non-invasive cancer diagnostics, presented findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a prospective, multi-center validation study evaluating its AI-powered, urine-based platform for early-stage prostate cancer detection.
The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), is the first to clinically validate PanGIA®'s novel approach—pairing proprietary chemistry with machine learning to detect cancer-specific biosignatures from a single, non-invasive urine sample.
"This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics," said Holly Magliochetti, CEO of PanGIA Biotech. "Our platform helps clinicians detect prostate cancer when intervention is most effective—without costly or invasive procedures."
Key findings presented included:
Study Cohort: 197 biopsy-confirmed prostate cancer patients and 84 healthy controls.
Classifier Performance: Achieved an F1 score of 0.843 with a recall of 0.967 in distinguishing cancer from non-cancer subjects.
Gleason Score Cohorts: Maintained high recall (>0.89) across Gleason scores 6 through 10, with F1 scores ranging from 0.799 to 0.838.
Non-Invasive Advantage: Demonstrated strong performance in detecting intermediate- and low-grade cancers, offering a less invasive alternative to traditional diagnostics.
Unlike invasive biopsies or blood-based tests that often miss early-stage cases, PanGIA's approach analyzes urinary biosignatures using proprietary AI models—eliminating the need for sequencing and enabling cost-effective, globally scalable testing.
Previously published in The Analyst, a journal of the Royal Society of Chemistry¹, the PanGIA platform is designed for diverse healthcare environments and holds promise for broad global adoption.
About PanGIA Biotech
PanGIA Biotech develops AI-integrated, urine-based liquid biopsy solutions designed for global scalability. The PanGIA® platform supports early detection, monitoring, and disease management—including cancer as early as Stage 1. With machine learning at its core, the platform deciphers biomolecular patterns to deliver accurate diagnostic insights. Backed by patents and peer-reviewed research, PanGIA is committed to reshaping healthcare through innovation. Learn more at www.PanGIABiotech.com.
¹ Lim FB, et al. "A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes." The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602724467/en/
Contacts
Media Contact Joy CappsMedia@PanGIABiotech.com 843-730-3857
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Federal appeals court upholds emergency subsistence hunt in Southeast Alaska village of Kake
The shoreline of Kake, a Tlingit village of about 500 people, is seen in 2012. (Photo provided by the Alaska Division of Community Affairs) A three-judge panel of the 9th U.S. Circuit Court of Appeals has ruled that the board which regulates subsistence hunting on federal lands within Alaska acted legally when it created an emergency hunt for a Southeast Alaska village during the COVID-19 pandemic emergency. The order, issued Monday, is the latest chapter of a five-year-old legal dispute stemming from a hunt authorized by the Federal Subsistence Board because the emergency in 2020 disrupted the normal food supply for the Southeast Alaska village of Kake. The emergency hunt resulted in the harvest of two moose and five deer, which were distributed to local residents. The state of Alaska later sued the board, arguing that approving the emergency hunt was beyond its authority and that the board acted inappropriately by delegating the hunt's administration to the Kake tribe. The Organized Village of Kake joined the lawsuit on the side of the Federal Subsistence board. The state's initial lawsuit was ruled moot by U.S. District Court Judge Sharon Gleason, but the 9th Circuit overturned that decision and sent the case back to Gleason, who ruled partially in favor of the state and partially in favor of the board. The state appealed again to the 9th Circuit, but on Tuesday, federal judges Carlos Bea (appointed by George W. Bush), Lucy Koh (Barack Obama) and Jennifer Sung (Joe Biden) confirmed that the hunt was legal. With Bea writing a statement on the ruling for all three judges, they said that the 1980 Alaska National Interest Lands Conservation Act permits access to subsistence resources on federal land, not just access to the land where those resources may be found. Bea cited Section 811 of ANILCA, in which Congress directed the Secretary of the Interior to ensure 'reasonable access to subsistence resources on the public lands.' 'Congress intended that the Secretary ensure that rural residents of Alaska have the reasonable opportunity to reach and use subsistence resources that can be found on federal land in Alaska,' Bea wrote. The decision implies that the board has the authority to create hunts, not just end them, as the state had argued. The judges also overruled part of a U.S. District Court decision that was partially in favor of the state, saying Gleason improperly handled prior instructions by the 9th Circuit. 'We hold that under Title VIII of (ANILCA), the Board has the power to authorize an emergency subsistence hunt on federal public lands for rural residents of the state of Alaska,' Bea wrote on behalf of the board. Court of Appeals decisions are considered final, unless appealed to a higher court, such as the U.S. Supreme Court. The decision by the three judges could also be appealed to the entire 9th Circuit. Doug Vincent-Lang, commissioner of the Alaska Department of Fish and Game, said in an emailed statement that the department doesn't agree with the decision. 'We are disappointed and disagree with this decision. It is both bewildering and perplexing that the court could rule against the plain language of the Alaska National Interest Claims Act, especially in light of the U.S. Supreme Court's ruling on Chevron deference. This ruling fundamentally alters the carefully crafted agreement that Congress made in adopting their language,' he said. 'We are currently reviewing our next steps.' Attorneys representing Kake said by email that the tribe is pleased with the result. 'Today's decision from the 9th Circuit is a significant victory for the Organized Village of Kake and Alaska Native subsistence rights,' they said. 'The 9th Circuit rejected the State of Alaska's shameful, politically-motivated attempt to gut ANILCA's subsistence provisions, and confirmed the Federal Subsistence Board's authority to open a small hunt to provide desperately needed access to healthy and traditional food to a remote Alaska community at the height of the COVID-19 pandemic. Today's victory is an affirmation of the promises that Congress made to protect subsistence rights, and comes at a time when the State is still seeking to erode those rights in other litigation and actions. The Tribe is very pleased with the result.'
Yahoo
a day ago
- Yahoo
Joe Biden Reveals How He's Fighting Prostate Cancer and Why He's 'Optimistic' He'll Beat the Disease
Former President Joe Biden has said he is 'optimistic' and "feeling good" about his cancer treatment after announcing his prostate cancer diagnosis in May Biden spoke about his cancer treatment for the first time as he attended a Memorial Day service in Delaware on May 30 'The expectation is we're going to be able to beat this,' Biden told reporters, according to CNNFormer President Joe Biden says he is feeling 'optimistic' since beginning his treatment for prostate cancer. Biden discussed his treatment for the first time publicly since announcing his prostate cancer diagnosis as he attended a Memorial Day service in New Castle, Del., on Friday, May 30. 'Well, the prognosis is good, you know, we're working on everything, it's moving along. I feel good. All the folks are optimistic,' Biden told reporters after speaking at the service in footage captured by ABC News. According to CNN, Biden shared that his treatment consists of him taking a daily pill over the next six weeks before starting another pill. The 82-year-old also said he is being treated by a 'leading surgeon who was diagnosed with the same type of cancer three decades ago,' per the outlet. 'The expectation is we're going to be able to beat this,' said Biden, per CNN. 'It's not in any organ, it's in — my bones are strong, it hadn't penetrated. So, I'm feeling good.' On May 18, Biden released a statement announcing that he had been diagnosed with 'aggressive' prostate cancer that has metastasized to his bones, after 'experiencing increasing urinary symptoms.' The cancer is characterized by a Gleason score of 9 (Grade Group 5),' which 'represents a more aggressive form of the disease,' according to the statement. Biden shared at the time that 'the cancer appears to be hormone-sensitive, which allows for effective management.' During his speech at the Memorial Day service in Delaware on Friday, Biden emotionally acknowledged his late son, former Delaware attorney general Beau Biden, following his passing from glioblastoma in 2015. 'I know for many of you, Memorial Day, like for us, is deeply personal. For the Bidens, this day is the 10th anniversary of the loss of my son Beau, who spent a year in Iraq. And to be honest, it's a hard day,' Biden said, per CNN. 'Being with all of you, quite frankly, makes things a little bit easier. It really does. So, thank you for allowing me to grieve with you.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Biden attended the service with Beau's son, Robert 'Hunter' Biden II, 18, according to CNN. The Biden family marked the 10th anniversary of Beau's death at a private mass together that same morning, the outlet reported. The politician's appearance with his family at the service comes after he attended his grandson Hunter's graduation from Salisbury School in Connecticut on May 23. Read the original article on People
Yahoo
a day ago
- Yahoo
ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success
With early detection of prostate cancer recognised as a critical part in reducing the disease's mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples. The US company's detection methodology involves analysing urinary biosignatures using AI and machine learning models, which the company asserts may prove beneficial over invasive biopsies or blood-based tests that may miss early-stage cases while also eliminating the need for sequencing. PanGIA's prospective study involved 197 biopsy-confirmed prostate cancer patients and 84 healthy controls, with the test demonstrating strong performance in detecting intermediate- and low-grade cancers, and high recall (>0.89) across Gleason scores 6 through 10. The AI/ML classification model was also found to be effective as measured by F1 score. The study's findings were presented at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place in Chicago, Illinois between 30 May and 3 June. 'This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics,' PanGIA CEO Holly Magliochetti. 'Our platform helps clinicians detect prostate cancer when intervention is most effective – without costly or invasive procedures.' Past research indicates that with early detection, the five-year survival rate for prostate cancer is over 99%. According to GlobalData's Pipeline Products database, there are 142 prostate cancer IVDs at active stages of development globally. Growing at a CAGR of 3.5%, the overall global IVD market is forecast to reach a valuation of around $45.9m by 2024, up from $32.4m in 2024, as per GlobalData analysis. In other prostate cancer news from ASCO 2025, researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. A recent large report by Philips on the passage of AI adoption and innovation in healthcare reflected that while clinicians are chiefly on board with the AI and recognise its value in healthcare settings, 46% of respondents stated that slow adoption of AI was contributing towards missed opportunities for early diagnosis and intervention. "ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
